Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma
Endocrinology and Metabolism
; : 211-216, 2014.
Article
em En
| WPRIM
| ID: wpr-80971
Biblioteca responsável:
WPRO
ABSTRACT
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-gamma, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Oncogenes
/
Proto-Oncogenes
/
Neoplasias da Glândula Tireoide
/
Transfecção
/
Fator A de Crescimento do Endotélio Vascular
/
Diagnóstico
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Endocrinology and Metabolism
Ano de publicação:
2014
Tipo de documento:
Article